Dare Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the annual meeting of stockholders held on June 24, 2021. Dare Bioscience, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol DARE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Five proposals were voted upon at the annual meeting. The results are as follows:
- Proposal 1 (Election of Directors): Stockholders elected three Class I directors (Jessica D. Grossman, M.D.; Susan L. Kelley, M.D.; Sophia Ononye-Onyia, Ph.D.) for a three-year term.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Proposal 3 (Share Issuance for Acquisition): Stockholders approved the issuance of common stock in connection with an acquisition to comply with Nasdaq Listing Rule 5635.
- Proposal 4 (Executive Compensation): Stockholders approved, on an advisory basis, the 2020 compensation of named executive officers.
- Proposal 5 (Adjournment): Stockholders approved the adjournment of the meeting if necessary to solicit additional proxies for Proposal 3.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors. The document serves as a disclosure of the completed voting process.
Key Facts for Investor Verification
- Verify the specific terms of the acquisition referenced in Proposal 3 to understand the dilution impact of the approved share issuance.
- Review the definitive proxy statement filed on May 14, 2021, for detailed biographies of the newly elected directors and the specific compensation packages approved.
- Confirm the status of the acquisition and the timing of the share issuance following the stockholder approval.